148
Participants
Start Date
June 1, 2003
Primary Completion Date
August 1, 2008
Study Completion Date
August 1, 2008
lenalidomide
10 mg orally once daily for 21 days out of a 28-day cycle (syncopated); subsequently amended (Amendment 1, dated 27 August 2003) to employ a continuous dosage regimen in which 10 mg was taken once daily for 28 day cycles (continuous). Subjects who initially began a syncopated regimen and who did not experience a dose-limiting adverse event were allowed to switch to the continuous regimen.
Mt. Sinai Medical Center, New York
Roswell Park Cancer Institute, Buffalo
University of Rochester- James P. Wilmot Cancer Center, Rochester
Western Pennsylvania Cancer Institute, Pittsburgh
Northwest Georgia Oncology - Wellstar Cancer Research, Marietta
Mayo Clinic, Jacksonville
University of Miami Sylvester Comp Cancer Center, Miami
Cancer & Blood Disease Center, Lecanto
The Cleveland Clinic Foundation, Cleveland
Mayo Clinic, Rochester
Midwest Cancer Research Group, Skokie
Rush-Presbyterian- St. Luke's Medical Center, Chicago
MD Anderson Cancer Center, Houston
Arizona Cancer Center, Scottsdale
Mayo Clinic, Scottsdale
Desert Hematology & Oncology Medical Group, Rancho Mirage
Oregon Health & Science University, Portland
Kaiser Permanente Northwest Region, Portland
Swedish Cancer Institute, Seattle
Arizona Cancer Center, Tucson
Stanford University Medical Center, Stanford
H. Lee Moffitt Cancer Center and Research Institute, Tampa
University of Chicago Medical Center, Chicago
Johns Hopkins Oncology Center, Baltimore
Dana-Farber Cancer Institute, Boston
Wayne State University School of Medicine, Detroit
University of Nebraska Medical Center, Omaha
New York Hospital-Cornell, New York
Memorial Sloan-Kettering Cancer Center, New York
Wake Forest University School of Medicine, Winston-Salem
Fred Hutchinson Cancer Research Center, Seattle
St. Johannes Hospital, Duisburg
Lead Sponsor
Celgene
INDUSTRY